法国工作年龄人群新冠疫苗犹豫:基于疫苗特征的调查实验
该调查实验于2020年7月在法国随机选取1942名18-64岁无SARS-CoV-2感染史的成年人,采用全因子设计评估疫苗有效性、严重副作用风险、生产地和接种地点对疫苗接受度的影响。
要点
- 疫苗犹豫与 outright refusal 均与女性、年龄(倒U型)、低教育水平、既往疫苗接种依从性差相关。
- 传达群体免疫益处可降低疫苗犹豫,但对 outright refusal 无影响。
- 疫苗接受度高度依赖疫苗特征,高效低风险且欧盟生产的疫苗接受度最高。
核心结论
- 在法国工作年龄人群中,新冠疫苗接受度取决于新疫苗特征和国家接种策略等多种因素。
研究设计与样本
- 调查实验于2020年7月从在线调查面板随机选取1942名18-64岁居住在法国、无SARS-CoV-2感染史的成年人,按性别、年龄、教育、家庭规模、地区和居住地分层以代表法国人口。
- 参与者完成背景和疫苗接种行为相关变量问卷后,按全因子设计随机分配接受不同群体免疫信息(三种)和全科医生推荐(两种),再完成8个离散选择任务评估基于假设疫苗特征的接受或拒绝。
- 采用两部分模型区分 outright vaccine refusal(在全部8个任务中均选择不接种)与 vaccine hesitancy(接受取决于疫苗特征)。
主要发现
- outright vaccine refusal 和 vaccine hesitancy 均与女性、年龄(倒U型关系)、较低教育水平、既往推荐疫苗接种依从性差、无特定慢性病报告显著相关。
- outright vaccine refusal 还与较低的新冠感知严重性相关;当传达群体免疫益处、在职个体以及有新冠经历(有症状或认识新冠患者)者中 vaccine hesitancy 较低。
临床怎么用
- 在设计新冠疫苗接种活动时,应优先考虑高效低风险且本地生产的疫苗以提高接受度。
- 针对女性、低教育水平、既往接种依从性差者需加强沟通,传达群体免疫益处可减少犹豫。
- 全科医生推荐对降低犹豫的作用需结合其他策略综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opinion polls on vaccination intentions suggest that COVID-19 vaccine hesitancy is increasing worldwide; however, the usefulness of opinion polls to prepare mass vaccination campaigns for specific new vaccines and to estimate acceptance in a country's population is limited. We therefore aimed to assess the effects of vaccine characteristics, information on herd immunity, and general practitioner (GP) recommendation on vaccine hesitancy in a representative working-age population in France. METHODS: In this survey experiment, adults aged 18-64 years residing in France, with no history of SARS-CoV-2 infection, were randomly selected from an online survey research panel in July, 2020, stratified by gender, age, education, household size, and region and area of residence to be representative of the French population. Participants completed an online questionnaire on their background and vaccination behaviour-related variables (including past vaccine compliance, risk factors for severe COVID-19, and COVID-19 perceptions and experience), and were then randomly assigned according to a full factorial design to one of three groups to receive differing information on herd immunity (>50% of adults aged 18-64 years must be immunised [either by vaccination or infection]; >50% of adults must be immunised [either by vaccination or infection]; or no information on herd immunity) and to one of two groups regarding GP recommendation of vaccination (GP recommends vaccination or expresses no opinion). Participants then completed a series of eight discrete choice tasks designed to assess vaccine acceptance or refusal based on hypothetical vaccine characteristics (efficacy [50%, 80%, 90%, or 100%], risk of serious side-effects [1 in 10 000 or 1 in 100 000], location of manufacture [EU, USA, or China], and place of administration [GP practice, local pharmacy, or mass vaccination centre]). Responses were analysed with a two-part model to disentangle outright vaccine refusal (irrespective of vaccine characteristics, defined as opting for no vaccination in all eight tasks) from vaccine hesitancy (acceptance depending on vaccine characteristics). FINDINGS: Survey responses were collected from 1942 working-age adults, of whom 560 (28·8%) opted for no vaccination in all eight tasks (outright vaccine refusal) and 1382 (71·2%) did not. In our model, outright vaccine refusal and vaccine hesitancy were both significantly associated with female gender, age (with an inverted U-shaped relationship), lower educational level, poor compliance with recommended vaccinations in the past, and no report of specified chronic conditions (ie, no hypertension [for vaccine hesitancy] or no chronic conditions other than hypertension [for outright vaccine refusal]). Outright vaccine refusal was also associated with a lower perceived severity of COVID-19, whereas vaccine hesitancy was lower when herd immunity benefits were communicated and in working versus non-working individuals, and those with experience of COVID-19 (had symptoms or knew someone with COVID-19). For a mass vaccination campaign involving mass vaccination centres and communication of herd immunity benefits, our model predicted outright vaccine refusal in 29·4% (95% CI 28·6-30·2) of the French working-age population. Predicted hesitancy was highest for vaccines manufactured in China with 50% efficacy and a 1 in 10 000 risk of serious side-effects (vaccine acceptance 27·4% [26·8-28·0]), and lowest for a vaccine manufactured in the EU with 90% efficacy and a 1 in 100 000 risk of serious side-effects (vaccine acceptance 61·3% [60·5-62·1]). INTERPRETATION: COVID-19 vaccine acceptance depends on the characteristics of new vaccines and the national vaccination strategy, among various other factors, in the working-age population in France. FUNDING: French Public Health Agency (Santé Publique France).
引用
- Schwarzinger M, Watson V, Arwidson P, et al. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021. PMID: 33556325. doi:10.1016/S2468-2667(21)00012-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。